Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.’s treatment for a rare genetic disorder after the Federal Trade Commission (FTC) sued to block the deal. In May, Maze and Sanofi announced a deal for the Pompe disease program MZE001. Sanofi agreed to pay $150 million in upfront cash, plus up to $600 million in milestones, for worldwide rights to a drug candidate targeting glycogen buildup. In a statement, Sanofi says that it was disappointed with the FTC’s actions, which would also delay potential advancements for Maze’s drug for Pompe disease to…
